1.
Hamid O, Lewis K, Weise A, McKean M, Papadopoulos KP, Crown J, Kim TM, Lakhani NJ, Kaczmar J, Kudchadkar R, Spira A, Rabinowits G, Kim K, Carvajal R, Williamson S, Ioffe E, Chen S, Mani J, Jankovic V, Brennan L, Kroog G, Sims T, Lowy I, Gullo G. Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. J of Skin [Internet]. 2023Mar.13 [cited 2024Jul.22];7(2):s179. Available from: https://jofskin.org/index.php/skin/article/view/1997